Navigation Links
European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012
Date:12/4/2011

SEATTLE, Dec. 5, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today an update on the status and progress of its European marketing authorization application ("MAA") for Pixuvri. CTI is seeking a license to market Pixuvri in the E.U. for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") who have failed two or more prior lines of therapy. CTI received the CHMP's day 180 list of outstanding issues, which unlike the day 120 letter, contained only one remaining major objection to CTI's MAA and items not deemed to be major issues. CTI plans on submitting its responses to the day 180 list of outstanding issues by December 19, 2011. If the responses satisfy the outstanding objection and the CHMP does not require an oral explanation a positive recommendation on the approval of Pixuvri could be made at the January 19th meeting of the CHMP.

"We believe we have made excellent progress working collegially with the E.U. rapporteurs on addressing items raised in the day 120 list of outstanding issues because we resolved all major objections other than the one major remaining objection in the day 180 letter," stated James A. Bianco,  M.D, CEO of CTI.

To address the remaining major objection, the CHMP required that CTI provide a literature review of mechanisms of rituximab resistance and analyses that demonstrate the efficacy of Pixuvri in patients with prior rituximab treatment, as well as information to address some additional questions that were not deemed to be major issues and could be addressed by additional analyses of currently available data.

On November 29th CTI met with the rapporteurs and team members from the EMA for a clarification meeting at which CTI and its clinical expert presented the results of its literature review, additional supportive analyses regarding the efficacy of pixantrone across response rates and progression free surviv
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
2. Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
3. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
4. X-ray Equipment - Top 5 European Markets
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. RSB Spine, LLC, Announces European Patent Allowance
7. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
8. Amgen Statement on European Investor Visit
9. European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive)
10. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
11. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... Carson Energy also announced they have ... transactions. AdvantaIRA Trust, LLC is the country’s largest self-directed ... fund positions using IRA’s does 2 things:, 1. It ... even if there current cash position will not allow ... for Carson and their investors to be able to ...
(Date:6/1/2015)... 01, 2015 The federal court overseeing ... amended the Case Management Order governing case selection for ... Amended Order which was issued in the U.S. ... 2015, directs the parties to submit a Proposed Case ... that outlines parameters and the process for selecting AbbVie-only ...
(Date:6/1/2015)... June 01, 2015 Atagi Plastic Surgery ... been named an Ultherapy® Ultra Treatment Provider ... and Skin Aesthetics is one of only six practices ... premier treatment provider. , Atagi Plastic Surgery and ... Denver area has led the practice to earn the ...
(Date:6/1/2015)... Washington, D.C. (PRWEB) June 01, 2015 Linda ... tired and had an irregular heartbeat. At first she thought ... soon found out it was much more than that. After ... valve disease. Linda admitted she felt afraid about what might ... as five million Americans are diagnosed with valve disease each ...
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
Breaking Medicine News(10 mins):Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2
... of Michigan scientists have found that a deficiency in a key ... type of adult brain cancer. The study, conducted in mice that ... and a way to screen for the disease early. Appearing ... in mice show for the first time that:, Glioblastoma, the ...
... A closer look at regulatory and clinical concerns with ... to an educational advisory by the International Society for ... issue of The Journal of Heart and Lung ... Thoracic transplant patients ...
... Georgia to use a new, cutting edge diagnostic ... outcomes. , , WOBURN, Mass., and VEDBAEK, Denmark, ... Medical Center in Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) ... than conventional methods to help their physicians, pharmacists and nurses ...
... addresses limitations of current randomized trials , , ... Inc . highlighted recent clinical panel presentations underscoring ... for treating asthma in adults and children. The company ... to mixed results in some randomized trials of eNO-guided ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced ... has approved the design of pivotal, Phase 2b/3 clinical ... drug for the acute treatment of patients with paroxysmal ... process. , , ATPace(TM) is a novel ...
... China, June 2 /PRNewswire-Asia/ -- China Nepstar Chain Drugstore,Ltd. ... "Company"), the largest drugstore,chain in China based on the ... Mr. Jason (Xinghua) Wu as the Chief Operating,Officer. ... overseeing,procurement, logistics, store development and store operations. He ...
Cached Medicine News:Health News:Most common brain cancer may start in neural stem cells 2Health News:Most common brain cancer may start in neural stem cells 3Health News:Most common brain cancer may start in neural stem cells 4Health News:More stringent evaluation on the use of generic medications in thoracic transplantation 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Clinical Utility of Exhaled Nitric Oxide Highlighted By American Thoracic Society Panel 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 3Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 4Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 2Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 3
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... The CTi Wrist Static is a solid, one-piece ... in a stable, neutral position. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Universal Wrist/Forearm Splint is ideal for post-surgical immobilization, post-fracture casting, wrist sprains and strains....
... wrist orthotic designed to limit the extension of the ... ,Indications: , Wrist reconstruction , Wrist ... Coles fracture - distal radius , Scaphoid ... ORIF - Open reduction and internal fixation for ...
Medicine Products: